原发性胆汁性肝硬化的治疗进展  

Advances in treatment of primary biliary cirrhosis

作　　者：秦华[1] 白石山[1] 

机构地区：[1]内蒙古医科大学,呼和浩特010051

出　　处：《临床肝胆病杂志》2013年第9期719-721,共3页Journal of Clinical Hepatology

摘　　要：原发性胆汁性肝硬化(PBC)是一种原因不明的慢性进行性肝内胆汁淤积性疾病,其发病率有逐年上升趋势。其治疗主要包括针对胆汁淤积的熊去氧胆酸、针对免疫异常发病机制的糖皮质激素或免疫抑制剂以及并发症的对症治疗,终末期患者适合肝移植。随着新药的不断研发和临床应用,对最新的治疗研究进展作一简要综述。结合近5年国内外PBC治疗的最新研究进展,观察哪一种方法可以根治PBC,不良反应最小,还须要进一步研究。Primary biliary cirrhosis （PBC） is a chronic progressive intrahepatic cholestatic disease of unknown cause, and its incidence is increasing year by year. The main therapies for PBC include ursodeoxycholic acid for cholestasis, glucocorticoid or immunosuppressant for abnormal immune response, and symptomatic treatment for complications; liver transplantation is suitable for end-stage cases. With continuous development and clinical application of new drugs, this paper reviews the latest global advances in the treatment of PBC over the last 5 years. However, further study is needed to identify the radical treatment with fewest adverse effects.

关 键 词：自身免疫疾病 肝硬化 胆汁性 熊去氧胆酸 

分 类 号：R575.2[医药卫生—消化系统]